RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Key Takeaways *RCC incidence is rising, with metastatic cases challenging to treat and costly, emphasizing the need for effective therapies. *Everolimus, an mTOR inhibitor, offers improved progression-free survival for patients failing sunitinib or sorafenib. *Budget impact analysis indicates potential cost savings with everolimus, despite high treatment costs in advanced RCC. *Economic evaluations must balance treatment benefits against healthcare system burdens, especially in end-of-life care.